Skip to main navigation Skip to search Skip to main content

Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation

  • Sung Han Yoon
  • , Tobias Schmidt
  • , Sabine Bleiziffer
  • , Niklas Schofer
  • , Claudia Fiorina
  • , Antonio J. Munoz-Garcia
  • , Ermela Yzeiraj
  • , Ignacio J. Amat-Santos
  • , Didier Tchetche
  • , Christian Jung
  • , Buntaro Fujita
  • , Antonio Mangieri
  • , Marcus Andre Deutsch
  • , Timm Ubben
  • , Florian Deuschl
  • , Shingo Kuwata
  • , Chiara De Biase
  • , Timothy Williams
  • , Abhijeet Dhoble
  • , Won Keun Kim
  • Enrico Ferrari, Marco Barbanti, E. Mara Vollema, Antonio Miceli, Cristina Giannini, Guiherme F. Attizzani, William K.F. Kong, Enrique Gutierrez-Ibanes, Victor Alfonso Jimenez Diaz, Harindra C. Wijeysundera, Hidehiro Kaneko, Tarun Chakravarty, Moody Makar, Horst Sievert, Christian Hengstenberg, Bernard D. Prendergast, Flavien Vincent, Mohamed Abdel-Wahab, Luis Nombela-Franco, Miriam Silaschi, Giuseppe Tarantini, Christian Butter, Stephan M. Ensminger, David Hildick-Smith, Anna Sonia Petronio, Wei Hsian Yin, Federico De Marco, Luca Testa, Nicolas M. Van Mieghem, Brian K. Whisenant, Karl Heinz Kuck, Antonio Colombo, Saibal Kar, Cesar Moris, Victoria Delgado, Francesco Maisano, Fabian Nietlispach, Michael J. Mack, Joachim Schofer, Ulrich Schaefer, Jeroen J. Bax, Christian Frerker, Azeem Latib, Raj R. Makkar*
*Corresponding author for this work
  • Cedars-Sinai Medical Center
  • Deutsches Herzzentrum München
  • University Hospital Hamburg-Eppendorf
  • Spedali Civili of Brescia
  • Hospital Universitaro Virgen de la Victoria
  • Hospital Clínico Universitario de Valladolid
  • Clinique Pasteur
  • University of Düsseldorf
  • San Raffaele Scientific Institute
  • Asklepios Klinik St. Georg
  • Zurich Center for Integrative Human Physiology (ZIHP)
  • Brighton and Sussex University Hospitals NHS Trust
  • Baylor College of Medicine
  • Kerckhoff Heart and Thorax Center
  • Cardiocentro Ticino Foundation
  • University of Catania
  • Leiden University
  • Gruppo Ospedaliero San Donato
  • University Hospital Pisa
  • University Hospitals Case Medical Center
  • National University Health System
  • General University Hospital
  • University Hospital of Vigo
  • Sunnybrook and Women's College Health Sciences Centre
  • Heart Center Brandenburg in Bernau
  • Technical University of Munich
  • St Thomas Hospital
  • Université Lille-Nord de France
  • Segeberger Kliniken
  • Hospital Clinicio San Carlos
  • Martin Luther University
  • University of Padova
  • Cheng Hsin General Hospital
  • IRCCS Policlinico San Donato
  • Erasmus University Medical Center
  • Intermountain Heart Institute
  • Hospital Universitario Central de Asturias
  • Scott and White Memorial Hospital

Abstract

Background Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR). Objectives This study sought to compare the outcomes of TAVR with early- and new-generation devices in symptomatic patients with pure native AR. Methods From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early- and new-generation devices. Results A total of 331 patients with a mean STS score of 6.7 ± 6.7 underwent TAVR. The early- and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 ± 6.7 vs. 7.6 ± 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p < 0.001). Compared with the early-generation devices, the new-generation devices were associated with a significantly higher device success rate (81.1% vs. 61.3%; p < 0.001) due to lower rates of second valve implantation (12.7% vs. 24.4%; p = 0.007) and post-procedural AR ≥ moderate (4.2% vs. 18.8%; p < 0.001). There were no significant differences in major 30-day endpoints between the 2 groups. The cumulative rates of all-cause and cardiovascular death at 1-year follow-up were 24.1% and 15.6%, respectively. The 1-year all-cause mortality rate was significantly higher in the patients with post-procedural AR ≥ moderate compared with those with post-procedural AR ≤ mild (46.1% vs. 21.8%; log-rank p = 0.001). On multivariable analysis, post-procedural AR ≥ moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001). Conclusions Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality.

Original languageEnglish
JournalJournal of the American College of Cardiology
Volume70
Issue number22
Pages (from-to)2752-2763
Number of pages12
ISSN0735-1097
DOIs
Publication statusPublished - 05.12.2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation'. Together they form a unique fingerprint.

Cite this